Sign up to save your podcasts
Or
Share CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
Host: Mikhail Kosiborod, MD
Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.
View all episodes
By ReachMDHost: Mikhail Kosiborod, MD
Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.